Added to YB: 2025-12-17
Pitch date: 2025-12-15
TRAW [bullish]
Traws Pharma, Inc.
-2.65%
current return
Author Info
Anders Research shares equity research primarily focused on micro/small/mid-cap biotechnology. We follow companies with mechanistically differentiated approaches to large market opportunities, with special focus in neuroscience. Sign up for the newsletter.
Company Info
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer.
Market Cap
$18.6M
Pitch Price
$2.26
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.77
P/E
-1.69
EV/Sales
4.29
Sector
Pharmaceuticals
Category
growth
A High-Risk (Degenerate) Gamble Before Year-End: Traws Pharma
TRAW: Phase 2 Covid antiviral retutrelvir readout due by year-end, targeting 20% of patients who can't take Paxlovid due to drug interactions. 10-day dosing vs Paxlovid's 5 days may reduce rebound rates. TXM flu asset provides BARDA stockpile optionality. OrbiMed-backed at $18M market cap.
Read full article (6 min)